Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLANYSE / NASDAQHealthcareSmall cap

$10.00+$0.48 (+5.0%)

Last close · Data as of Nov 20, 2026

Market cap
$2.1B
Revenue
$67.7M
Net margin
-609.9%
ROCE
-65.7%

+24.4% over the last year

Intellia Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-15.5%
3M
-19.6%
6M
-18.4%
1Y
+24.4%
5Y
-92.3%

52-week range

Day change +$0.48 (+5.0%) from $9.52 to $10.00 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NTLA, bought on each weekday since 2021.

News & filings

What Intellia Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 413 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 16.9% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases.

Read moreShow less

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
116.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$2.1B
P/B
3.1x
EV / Sales
25.2x
P/S
30.5x
52-week high
$17.84
52-week low
$8.04

Profitability

Operating margin
-651.7%
Net margin
-609.9%
EBITDA margin
-628.2%
ROE
-61.5%
ROCE
-65.7%
ROIC
-57.2%
ROA
-49.0%
Asset turnover
0.08

Growth

Revenue
$67.7M
Revenue growth, 1Y
16.9%
Revenue CAGR, 3Y
9.1%
Net profit growth, 1Y
-20.5%
Free cash flow
-$395.9M

Solvency

Current ratio
5.08
Debt / Equity
0.14
Debt / Assets
0.11
CFO / Net profit
0.96
Cash / Market cap
21.8%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$67.7M
Gross profit$67.7M
Operating expenses$508.7M
Research and development$388.9M
Selling, general and administrative$119.8M
Operating income-$441.0M
Interest and other$28.3M
Pretax income-$412.7M
Tax and other$0.00
Net income-$412.7M

Revenue and net profit

Revenue grew 16.9% in FY2025; net profit is the dashed line.

Intellia Therapeutics, Inc. revenue and net profit by fiscal year
Intellia Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$52.1M-$474.2M
FY2023$36.3M-$481.2M
FY2024$57.9M-$519.0M
FY2025$67.7M-$412.7M

Cash flows

FY2025: -$394.7M from operations, -$395.9M free after investment (dashed).

Intellia Therapeutics, Inc. operating and free cash flow by fiscal year
Intellia Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$333.3M-$391.7M
FY2023-$394.1M-$408.1M
FY2024-$348.9M-$354.7M
FY2025-$394.7M-$395.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$67.7M+16.9%1Y
EBITDA
-$425.1M
Net profit
-$412.7M
Cash from operations
-$394.7M
Free cash flow
-$395.9M
Revenue CAGR, 3Y
9.1%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$67.7M-$425.1M-$412.7M-$395.9M-61.5%+16.9%-20.5%

Monthly returns

Month-by-month returns of NTLA across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$842.1M
Liabilities$170.7M
Equity$671.4M
Paid-in capital$3.3B
Retained earnings-$2.6B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NTLA highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Intellia Therapeutics, Inc. (this company)25.2x

Not shown (no positive earnings and no EV / Sales): Kodiak Sciences Inc., Trevi Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Intellia Therapeutics, Inc.NTLAthis company$2.1B—3.1x-61.5%—
Kodiak Sciences Inc.KOD$2.1B—13.6x-146.1%—
Aurinia Pharmaceuticals Inc.AUPH$2.1B7.3x3.6x49.4%15.2x
Clover Health Investments, Corp.CLOV$2.1B-24.6x6.8x-27.7%—
NovoCure LimitedNVCR$2.1B—6.1x-40.0%—
Recursion Pharmaceuticals, Inc.RXRX$2.0B-3.1x1.8x-57.0%-2.4x
Progyny, Inc.PGNY$2.0B34.1x3.9x11.3%21.2x
Omnicell, Inc.OMCL$2.0B967.3x1.6x0.2%21.5x
Trevi Therapeutics, Inc.TRVI$2.0B-46.3x10.8x-23.3%-45.9x
Peer median—2.1x5.0x-25.5%15.2x

Year-to-date ROI

NTLA since 1 January, against earlier years.

Historical volatility

NTLA's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Intellia Therapeutics, Inc. operating margin by fiscal year
Intellia Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-879.0%
FY2023-1420.3%
FY2024-923.0%
FY2025-651.7%
LineFY2025
Operating expensesOperating Expense$508.7M
Research and developmentResearch And Development$388.9M
Total expensesTotal Expenses$508.7M
Pretax incomePretax Income-$412.7M

Learn while you research

Academy chapters picked for Intellia Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →